Drug Profile


Alternative Names: Anti-CD123 CAR-T Cells-Cellectis

Latest Information Update: 18 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cellectis
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Haematological malignancies

Most Recent Events

  • 17 Aug 2017 Cellectis initiates enrolment in a phase I trial for Haematological malignancies (In adults, In the elderly, Second-line therapy or greater) in USA
  • 27 Jul 2017 Cellectis and MolMed agree to develop and produce allogeneic CAR-T products for Cancer
  • 28 Jun 2017 Phase-I clinical trials in Haematological malignancies (Newly diagnosed) in USA (IV) (NCT03203369)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top